An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Vaccine

• Publication date

  2005-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2005.03.042PMID 16005749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.

  2005cited by this paper
• rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers

  2005cited by this paper
• Structure of the dengue virus envelope protein after membrane fusion

  2004cited by this paper
• Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii.

  2003cited by this paper
• Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

  2003cited by this paper
• Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.

  2003cited by this paper
• Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.

  2003cited by this paper
• Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.

  2003cited by this paper
• A ligand-binding pocket in the dengue virus envelope glycoprotein

  2003cited by this paper
• Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

  2003cited by this paper
• Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

  2002cited by this paper
• Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' noncoding sequences.

  2001cited by this paper
• Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.

  2000cited by this paper
• Live attenuated tetravalent dengue vaccine.

  2000cited by this paper
• Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice.

  1997cited by this paper
• Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells.

  1996cited by this paper
• Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.

  1996cited by this paper
• A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.

  1994cited by this paper
• Progress in the Development of Recombinant Vaccines Against Dengue and Other Arthropod-Borne Flaviviruses

  1994cited by this paper
• Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones

  1991cited by this paper
• Regulated Expression Allows High Level Production and Secretion of HIV-1 gp120 Envelope Glycoprotein in Drosophila Schneider Cells

  1991cited by this paper
• Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.

  1990cited by this paper
• Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies.

  1990cited by this paper
• The dengue viruses

  1990cited by this paper
• Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection.

  1989cited by this paper
• Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses.

  1988cited by this paper
• Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection.

  1987cited by this paper
• Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.

  1987cited by this paper
• Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies.

  1985cited by this paper
• Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.

  1984cited by this paper
• Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay.

  1983cited by this paper
• Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.

  1982cited by this paper
• "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

  1981cited by this paper
• Infection of an Aedes aegypti cell line with infectious arbovirus-antibody complexes.

  1976cited by this paper
• Multiple forms of SS → DS RNA polymerase activity in reovirus-infected cells

  1974cited by this paper
• Cell lines derived from late embryonic stages of Drosophila melanogaster.

  1972cited by this paper
• Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion.

  1970cited by this paper
• Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines.

  1967cited by this paper
• Altered Reactivity to Measles Virus: Atypical Measles in Children Previously Immunized With Inactivated Measles Virus Vaccines

  1967cited by this paper
• Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

  1958cited by this paper

• Overcoming Challenges in Dengue Vaccine Development: Advanced Delivery Approaches.

  2026cites this paper
• VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.

  2026cites this paper
• [Dengue treatments and vaccines].

  2025cites this paper
• Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines

  2025cites this paper
• VSA-2, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine

  2025cites this paper
• Dengue Transmission in Bangladesh: A Retrospective Analysis of Case Trends and Mortality

  2025cites this paper
• Dengue Vaccines.

  2025cites this paper
• Neutralization Tests for Quantification of Specific Antibodies Against Yellow Fever Virus.

  2025cites this paper
• Dengue Investigation Research in Bangladesh: Insights From a Scoping Review

  2025cites this paper
• Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.

  2025cites this paper
• Current Dengue Virus Vaccine Developments and Future Directions

  2025cites this paper
• From bark to bench: innovations in QS-21 adjuvant characterization and manufacturing

  2025cites this paper
• Unlocking Hope: Paving the Way for a Cutting-Edge Multi-Epitope Dengue Virus Vaccine

  2024cites this paper
• Approaches of dengue control: vaccine strategies and future aspects

  2024cites this paper
• The recombinant truncated envelope protein of West Nile virus adjuvanted with Alum/CpG induces potent humoral and T cell immunity in mice

  2023influential citation
• Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies.

  2023cites this paper
• Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art

  2023cites this paper
• Recent outbreak of dengue in Bangladesh: A threat to public health

  2023cites this paper
• Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development

  2021cites this paper
• Targets and strategies for vaccine development against dengue viruses.

  2021cites this paper
• Mammalian animal models for dengue virus infection: a recent overview

  2021cites this paper
• Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.

  2021cites this paper
• Dengue Virus: Infection, Immunological Response, and Vaccine Development

  2021cites this paper
• Dengue vaccine: an update

  2021cites this paper
• Dengue and human health: A global scenario of its occurrence, diagnosis and therapeutics

  2021cites this paper
• A Review on Dengue Vaccine Development

  2020cites this paper
• Anti-dengue Vaccines: From Development to Clinical Trials

  2020cites this paper
• Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection

  2020cites this paper
• Immunological Assays used to Support Efficacy of Zika Virus Vaccines

  2019cites this paper
• Current prevention and potential treatment options for dengue infection.

  2019cites this paper
• Current Status of Vaccines against Dengue Virus Current Status of Vaccines against Dengue Virus

  2019cites this paper
• Animal Models for Dengue and Zika Vaccine Development.

  2018cites this paper
• Current Status of Vaccines against Dengue Virus

  2018cites this paper
• Enhanced expression of dengue virus EDIII-based tetravalent antigen protein using transgenic rice callus

  2018cites this paper
• Chapter 2 Inactivated Viral Vaccines

  2017cites this paper
• Evaluation of a Tetravalent DNA Vaccine against Dengue: Integrating Biochemical Studies on Dengue Virus Envelope Protein to a Domain-Based Antigen Design.

  2017cites this paper
• Marmosets (Callithrix jacchus) as a non-human primate model for evaluation of candidate dengue vaccines: induction and maintenance of specific protective immunity against challenges with clinical isolates.

  2017cites this paper
• Demostración de la capacidad protectora de candidatos vacunales contra el virus del dengue basados en la proteína de la cápsida y el oligodesoxinucleótido 39M

  2016cites this paper
• Current perspectives on dengue episode in Malaysia.

  2016cites this paper
• Dengue vaccine: an update on recombinant subunit strategies.

  2016cites this paper
• Different Approaches to Counteracting Hepatitis C Virus and Chikungunya Virus Infections

  2016cites this paper
• Dengue Fever: Causes, Complications, and Vaccine Strategies

  2016cites this paper
• Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?

  2016cites this paper
• An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques

  2015cites this paper
• Trials and tribulations on the path to developing a dengue vaccine.

  2015cites this paper
• FACULDADE DE MEDICINA DE RIBEIRÃO PRETO CENTRO DE PESQUISA EM VIROLOGIA PROGRAMA DE PÓS-GRADUAÇÃO EM CLÍNICA MÉDICA PADRONIZAÇÃO DE UMA NOVA TÉCNICA PARA DETECÇÃO DE ANTICORPOS NEUTRALIZANTES ANTI-DENGUE BASEADA NA RT-PCR EM TEMPO REAL

  2015cites this paper
• Dengue vaccines: challenges, development, current status and prospects.

  2015cites this paper
• Host cellular regulatory networks in dengue virus-human interactions

  2015cites this paper
• Development of a capillary zone electrophoresis method for dose determination in a tetravalent dengue vaccine candidate

  2015cites this paper
• Immunogenicity and Efficacy of Flagellin-Envelope Fusion Dengue Vaccines in Mice and Monkeys

  2015cites this paper
• Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

  2015cites this paper
• Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.

  2015cites this paper
• Next generation dengue vaccines: A review of the preclinical development pipeline.

  2015cites this paper
• Preclinical and clinical development of a dengue recombinant subunit vaccine.

  2015cites this paper
• Development of a Dengue Vaccine in Humans: So Near, Yet So Far

  2015cites this paper
• Development of novel inactivated poliovirus vaccines: Breaking away from convention

  2015cites this paper
• The protein DIIIC‐2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV‐2

  2015cites this paper
• Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines

  2015cites this paper
• Advances in the understanding, management, and prevention of dengue.

  2015cites this paper
• Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures

  2015cites this paper
• Trials and Tribulations on the Path to Developing a Dengue Vaccine.

  2015cites this paper
• Complementary alternative medicine use among patients with dengue fever in the hospital setting: a cross-sectional study in Malaysia

  2015cites this paper
• Production and testing of dengue virus strains suitable for human infection studies.

  2014cites this paper
• Clinical implications and treatment of dengue.

  2014cites this paper
• Evaluation of dengue virus strains for human challenge studies.

  2014cites this paper
• Developing a dengue vaccine: progress and future challenges

  2014cites this paper
• Inactivated Viral Vaccines

  2014cites this paper
• Dengue virus vaccine development.

  2014influential citation
• Recent progress in dengue vaccine development

  2014cites this paper
• Utility, Limitations, and Future of Non-Human Primates for Dengue Research and Vaccine Development

  2014cites this paper
• Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III.

  2013cites this paper
• Identifying protective dengue vaccines: guide to mastering an empirical process.

  2013cites this paper
• Current progress in dengue vaccines

  2013cites this paper
• Can non-human primates serve as models for investigating dengue disease pathogenesis?

  2013cites this paper
• An Alphavirus Vector-Based Tetravalent Dengue Vaccine Induces a Rapid and Protective Immune Response in Macaques That Differs Qualitatively from Immunity Induced by Live Virus Infection

  2013cites this paper
• Dengue Vaccines: Strongly Sought but Not a Reality Just Yet

  2013cites this paper
• A Chimeric Dengue Virus Vaccine using Japanese Encephalitis Virus Vaccine Strain SA14-14-2 as Backbone Is Immunogenic and Protective against Either Parental Virus in Mice and Nonhuman Primates

  2013cites this paper
• Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4′-aminomethyl-trioxsalen) is highly immunogenic in mice

  2013cites this paper
• Challenges in reducing dengue burden; diagnostics, control measures and

  2013cites this paper
• Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae.

  2013cites this paper
• Experimental Dengue Vaccines

  2013cites this paper
• The use of Drosophila S2 cells in R&D and bioprocessing

  2013cites this paper
• Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesis.

  2013cites this paper
• Challenges in reducing dengue burden; diagnostics, control measures and vaccines

  2013cites this paper
• Recombinant envelope protein-based enzyme immunoassay for IgG antibodies is comparable to neutralization tests for epidemiological studies of dengue infection.

  2013cites this paper
• Rational Discovery of Dengue Type 2 Non‐Competitive Inhibitors

  2013cites this paper
• DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice

  2013cites this paper
• Dengue vaccines: recent developments, ongoing challenges and current candidates

  2013cites this paper
• Olive baboons: a non-human primate model for testing dengue virus type 2 replication.

  2013cites this paper
• dentifying protective dengue vaccines : Guide to mastering an mpirical process cott

  2013cites this paper
• MULTIVALENT STRATEGIES AGAINST VIRUS PATHOGENS

  2013cites this paper
• Identification of cross-neutralizing B-cell epitopes on the dengue virus envelope glycoprotein and their application in synthetic peptide based vaccine design

  2013cites this paper
• Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses

  2012cites this paper
• Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant.

  2012cites this paper
• A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits

  2012cites this paper
• Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.

  2012cites this paper
• The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice

  2012cites this paper
• Koutango: under reported arboviral disease in West Africa

  2012cites this paper
• Testing of Novel Dengue Virus 2 Vaccines in African Green Monkeys: Safety, Immunogenicity, and Efficacy

  2012cites this paper
• Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

  2011cites this paper